Headquartered in Minneapolis, MN Fiscal year ends June NASDAQ: TECH bio-techne.com
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing high-quality reagents, analytical instruments, and precision diagnostics used across biopharma, academic research, and clinical diagnostic laboratories. The company operates through two reportable segments: Protein Sciences, which supplies specialized proteins such as cytokines and growth factors, immunoassays, antibodies, and reagents along with protein analysis platforms; and Diagnostics and Spatial Biology, which develops spatial biology products, carrier screening and oncology kits, blood chemistry and blood gas quality controls, hematology instrument controls, and bulk and custom reagents for the in vitro diagnostic market. Its portfolio is organized into three customer-facing brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics. The company operates in 34 locations worldwide with approximately 3,000 employees and offers more than 500,000 products. In June 2026, Bio-Techne entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Updated
Watch the video below for a discussion about Microsoft’s (NASDAQ: MSFT) | MSFT Price Prediction strategic shift under CEO Satya Nadella, focusing on future technologies like AI compared to previous leadership. The…
Thursday's premarket session was slightly positive, and it would take something major to push the markets in one direction or the other.
Tuesday's top analyst upgrades and downgrades included Accenture, Analog Devices, Apple, Baxter International, Best Buy, Coterra Energy, Emerson Electric, Johnson Controls, Lam Research, Micron Technology, Qualcomm, Silvergate Capital, Tapestry and Walt Disney.
Wednesday's top analyst upgrades and downgrades included Delta Air Lines, Hasbro, Illumina, Lululemon Athletica, Micron Technologies, Nike, Penn National, Shopify, Southwest Airlines, Starbucks and Zynga.
Wednesday's top analyst upgrades and downgrades included AMC Entertainment, Apple, Cerence, Chipotle Mexican Grill, Ciena, Dollar Tree, Freshpet, LATAM Airlines, Nio, Peloton Interactive, Ping, Tesla and Walt Disney.
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
The top analyst upgrades, downgrades and initiations on Tuesday included Cars.com, Comerica, Cummins, Enbridge, Lyft, Micron Technology, Roku, Stryker, Uber Technologies, Visa and Western Digital.
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boston Scientific, Etsy, General Electric, Morgan Stanley, SeaWorld, Skechers, Shopify, Square and Tesla.
According to a recent analyst report by Janney, the National Institute of Health budget that was approved last Friday could be a big boost for some select biopharma stocks.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
The top analyst upgrades, downgrades and initiations seen on Thursday include Baker Hughes, Cree, Freeport-McMoRan, GrubHub, Silver Wheaton, Dynegy, Panera Bread and Ulta Beauty.
Jon OggInvestors frequently see analyst upgrades and Buy ratings from Wall Street research calls, but they often do not get to see the so-called Sell ratings. 24/7 Wall St. reviews many fresh…
Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss. Here were the big movers: Barrier Therapeutics (NASDAQ: BTRX) ran way up…
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing high-quality reagents, analytical instruments, and precision diagnostics used across biopharma, academic research, and clinical diagnostic laboratories.
24/7 Wall St.'s 12-month price target for TECH is $83.56, rated Buy. The Wall Street consensus target is $70.50. TECH price prediction →
